Details of the Drug

General Information of Drug (ID: DMTMA5W)

Drug Name
GV-971
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Approved in China [1]
Cross-matching ID
TTD ID
D0FS5O

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Amyloid beta A4 protein (APP) TTE4KHA A4_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Amyloid beta A4 protein (APP) DTT APP 1.60E-02 -0.07 -0.31
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer's Disease. Sci Eng Ethics. 2023 Jan 10;29(1):2.
2 Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803.